Teva Pharmaceutical Indus... (TEVA)
NYSE: TEVA
· Real-Time Price · USD
16.39
0.20 (1.24%)
At close: May 05, 2025, 3:59 PM
16.40
0.06%
After-hours: May 05, 2025, 07:57 PM EDT
1.24% (1D)
| Bid | 16.37 |
| Market Cap | 18.78B |
| Revenue (ttm) | 16.55B |
| Net Income (ttm) | -1.64B |
| EPS (ttm) | -1.45 |
| PE Ratio (ttm) | -11.3 |
| Forward PE | 4.95 |
| Analyst | Buy |
| Ask | 16.53 |
| Volume | 16,035,191 |
| Avg. Volume (20D) | 11,841,320 |
| Open | 16.81 |
| Previous Close | 16.19 |
| Day's Range | 16.02 - 16.86 |
| 52-Week Range | 12.47 - 22.80 |
| Beta | 0.72 |
About TEVA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and cr...
Sector Healthcare
IPO Date Feb 16, 1982
Employees 33,892
Stock Exchange NYSE
Ticker Symbol TEVA
Website https://www.tevapharm.com
Analyst Forecast
According to 6 analyst ratings, the average rating for TEVA stock is "Buy." The 12-month stock price forecast is $24.5, which is an increase of 49.48% from the latest price.
Stock ForecastsNext Earnings Release
Teva Pharmaceutical Industries Limited is scheduled to release its earnings on May 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
20 hours ago
TEVA stock has given up its prior gain. Teva Pharm...
Unlock content with
Pro Subscription
22 hours ago
Teva Pharmaceuticals shares are trading higher after the company announced FDA Approval for SELARSDI Injection as an interchangeable with the reference biologic Stelara
